It looks like Valeritas, which is developing insulin pumps for Type 2 diabetes, is in the midst of raising another big round of cash.
The New Jersey medical device company filed paperwork with the SEC indicating it’s raised about $22 million in a round that could go as high as $45 million.
Personalized medicine (PMx), medical treatment tailored to specific patient populations based on their genetic or molecular biology profiles, has long been heralded as the next big thing in healthcare. It’s been about 16 years since Genentech launched Herceptin, a drug for breast cancer patients with a specific genetic mutation. At the time, Herceptin seemed to usher in a revolution for how drugs would be developed and patients would be cured.
In that new version of care, drugs could be tailored to a patient’s specific biochemical profile, dramatically improving efficacy rates and reducing the system-wide costs and complications associated with one-size-fits-all medications. For pharmaceutical manufacturers, this approach had the potential to improve sales and profits through a radically new business model: differentiated products for segmented populations (see “A Strategist’s Guide to Personalized Medicine,” by Avi Kulkarni and Nelia Padilla McGreevy, s+b, Winter 2012).
Storrer will oversee strategy, expansion and operation of Strand Genomics Inc., the wholly owned subsidiary of Strand Life Sciences in North America. Strand is a leader in technology innovations for personalized medicine using genomics in over 2,000 clinical and research institutions worldwide. By enhancing sequence-based diagnostics and clinical genomic data interpretation using a strong foundation of computational, scientific, and medical expertise Strand is bringing individualized medicine to the world.
“We are excited to have Scott Storrer join our team,” said Dr. Vijay Chandru, Chairman and CEO of Strand. “Storrer’s twenty plus years of executive experience leading and growing profitable businesses in the U.S. healthcare industry across payer, provider and personalized medicine sectors will help develop a strong presence for Strand in North America.”
Originating as a solution to educate health workers in developing countries, emocha is now a powerful platform that allows researchers and clinicians to use mobile data capture, health education, and communication to address the challenges of adherence, linkage to care, and patient data management across a myriad of use cases. Sebastian Seiguer, CEO and Founder of emocha, and Morad Elmi, Director of Marketing, spoke with us about the latest from this Baltimore-based startup.
The adoption of IT in healthcare systems has, in general, followed the same pattern as other industries. In the 1950s, when institutions began using new technology to automate highly standardized and repetitive tasks such as accounting and payroll, healthcare payors and other industry stakeholders also began using IT to process vast amounts of statistical data. Twenty years later, the second wave of IT adoption arrived. It did two things: it helped integrate different parts of core processes (manufacturing and HR, for example) within individual organizations, and it supported B2B processes such as supply-chain management for different institutions within and outside individual industries. As for its effects on the healthcare sector, this second wave of IT adoption helped bring about, for example, the electronic health card in Germany. It was also a catalyst for the Health Information Technology for Economic and Clinical Health Act in the United States—an effort to promote the adoption of health-information technology—and the National Programme for IT in the National Health Service in the United Kingdom. Regardless of their immediate impact, these programs helped create an important and powerful infrastructure that certainly will be useful in the future.
Biopharma firms continued to attract US venture capital investment in Q1 according to new analysis by PricewaterhouseCoopers (PwC), which says the number of firms that received backing is encouraging.
The analysis – part of the “MoneyTree” report published by PwC and the National Venture Capital Association in April – showed that the biotechnology sector garnered $1.1bn from venture capitalists in Q1, up from $871m in the equivalent period in 2013.
Anyone who wants a job next year at Anne Arundel Medical Center — whether as a surgeon or security guard — will have to prove they don’t smoke or use tobacco.
The Annapolis hospital’s new hiring policy might be controversial, but it is legal in Maryland and more than half of the United States. And it’s a type of job screening that is gaining favor with employers — from hospitals to companies such as Alaska Airlines — trying to control rising health costs and cultivate a healthier, more productive workforce.
Former Johns Hopkins University college student Alex Koren wants to make a difference.
Koren feels he has a better opportunity of doing that by dropping out of Johns Hopkins, and devoting all of his time to his ideas on a Thiel Fellowship.
Two Montgomery County companies each took home the top prize of $100,000 in their category as part of the 2014 InvestMaryland Challenge.
Bethesda-based life sciences company, Brain Sentry, won for its helmet-mounted sensor used to identify team sport players who should be evaluated for a concussion. Gaithersburg-based IT company, ClickMedix, won its catergory for technology aimed at helping physicians and health organizations maximize the number of patients they are able to serve.
Both companies were also recipients of the Kauffman FastTrac award entitling them to enroll in any FastTrac course and receiving a copy of the new Kauffman release — “Chance & Intent: Managing the Risks of Innovation & Entrepreneurship”
Rockville biotechnology company Cellphire is the latest receipient of funding via the State’s InvestMaryland program, receiving $1 million last month!
Cellphire is developing stabilized cellular products, including freeze-dried platelets that can be stored for years and used in a range of advanced therapeutic and diagnostic applications including sports medicine, plastic surgery and dentistry. The company received a contract last year worth up to $57 million from the Biomedical Advanced Research Defense Authority, a division of U.S. Department of Health & Human Services. The InvestMaryland funding will be used to continue development of the company’s freeze-dried platelet product, Thrombosomes, and move it closer to winning FDA approval.
